# Intra-Anally Administered Artesunate in Patients With High-Grade Anal Intraepithelial Neoplasia (AIN 2/3)

> **NCT03100045** · PHASE1 · COMPLETED · sponsor: **Johns Hopkins University** · enrollment: 18 (actual)

## Conditions studied

- HPV-Related Anal Intraepithelial Neoplasia
- AIN2/3
- Artesunate
- Alternative Treatment
- Anal Dysplasia
- Precancerous Conditions
- Human Papilloma Virus

## Interventions

- **DRUG:** Artesunate Suppositories

## Key facts

- **NCT ID:** NCT03100045
- **Lead sponsor:** Johns Hopkins University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-20
- **Primary completion:** 2021-10-06
- **Final completion:** 2021-10-06
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2021-11-03

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03100045

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03100045, "Intra-Anally Administered Artesunate in Patients With High-Grade Anal Intraepithelial Neoplasia (AIN 2/3)". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03100045. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*